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Cardiac AmyloidosisWe thank Barison et al. for their interest in our
paper (1). Cardiac amyloidosis is gaining signiﬁcant
exposure in the cardiac magnetic resonance (CMR)
community because of the characteristic and near
pathognomonic ﬁndings with the technique. We
reported the ﬁrst study that speciﬁcally aimed to
differentiate between the light chain (AL) and trans-
thyretin (ATTR) subtypes of amyloidosis through re-
trospective analysis of studies performed in multiple
hospitals referring toa specialist amyloidosis center (1).
We did not include right ventricular volumes,
mass, and ejection fraction in the analyses because
not all studies included sufﬁcient images to perform
accurate analysis. Right ventricular morphology data
(particularly right ventricular mass) are less repro-
ducible, even in single center studies (2), and in this
series axial data sets had rarely been routinely
obtained (3). The Query Amyloid Late Enhancement
score, a novel late gadolinium enhancement anal-
ysis, was designed to be a simple add-on to standard
reporting. Various versions of the Query Amyloid
Late Enhancement score were devised, incor-
porating other CMR variables, but we and the re-
viewers decided to report the score independently,
without including potentially confounding factors,
because it was a standalone predictor of amyloidtype. The thinness of the atrial chambers precludes
their use as a reliable measurement when assessing
late gadolinium enhancement. Altered gadolinium
kinetics, already widely reported in cardiac amyloi-
dosis, appear very similar between amyloid types (4),
but further quantitative assessment in this multiple
center, multiple protocol study was not feasible.
Overall, the comments highlight the limitations of
any retrospective study, but we would like to reinforce
the view that our ﬁndings were actually strengthened
by the study design. The data were derived from
nonstandardized protocols performed on various
scanners; however, despite this, an obvious difference
between the amyloid subtypes was shown. Our results
are therefore relevant to nonspecialist CMR centers,
which often raise the possibility of amyloidosis for the
clinicians who refer patients for CMR. Prospective
studies with specialist amyloid protocols may seem
ideal; however, in the real world, our results are
applicable to all CMR operators.Jason N. Dungu, MBBS, BSc*
Lisa J. Anderson, MD
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